RxDoctor Payments Data

Kataneh Maleki, MD

Clinical Cardiac Electrophysiology · Edison, NJNPI 1396706651

Payments from drug & device makers

$10,020in general payments, 2019–2025

Across 213 payments — averaging $47.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Boston Scientific$2K
  • Abbott$859
  • Biotronik Inc.$398
  • Biosense Webster, Inc.$340
  • E.r. Squibb & Sons, L.L.C.$272
  • plus $2K from 30 others

What the payments were for

  • Travel & lodging$3,40334%
  • Food & beverage$6,61766%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,020 in reported general payments places this provider in the 25th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

See all clinical cardiac electrophysiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$309,821
Medicare patients
659
Services billed
3,114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban211$232,003
XareltoRivaroxaban73$66,925
MultaqDronedarone Hcl50$57,925
EntrestoSacubitril/Valsartan33$47,659
FarxigaDapagliflozin Propanediol28$19,361
Dofetilide60$10,657
Mexiletine Hcl52$4,401
Flecainide Acetate88$4,132
SotalolSotalol Hcl196$3,752
Metoprolol Succinate91$2,181
Midodrine Hcl18$1,464
Metoprolol Tartrate118$1,006
Diltiazem 24hr Er (Cd)Diltiazem Hcl32$671
Dilt-XrDiltiazem Hcl15$575
Digoxin22$574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$195$232,003211 claims
Johnson & JohnsonXarelto$268$66,92573 claims
Sanofi-aventis U.S. LLCMultaq$134$57,92550 claims
NovartisEntresto$52$47,65933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

Other clinical cardiac electrophysiology in Edison

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →